WASHINGTON (MedPage Today) -- The FDA has added increased risk of myocardial infarction and dyslipidemia to prescribing information for the HIV drug fosamprenavir calcium (Lexiva) in tablet and oral suspension.
FDA Updates HIV Drug Info to Include MI DangerCourtesy MedPage Today Infectious Disease Fri, 12/04/2009 - 10:04
WASHINGTON (MedPage Today) -- The FDA has added increased risk of myocardial infarction and dyslipidemia to prescribing information for the HIV drug fosamprenavir calcium (Lexiva) in tablet and oral suspension. More related itemsDoor-to-Balloon Time Shorter With EMT Diagnosis...
Web-Based Program Fails to Boost Care After MI...
K2 Linked to Heart Attacks in Teens (CME/CE)
Alcohawk Precision Digital Alcohol Breath Tester
Genuine Magnetrainer ER (Extended Range) Mini...
|
Popular by tags WeekMonth |
Post new comment